TY - JOUR
T1 - New N-allylthiourea derivatives
T2 - Synthesis, molecular docking and in vitro cytotoxicity studies
AU - Widiandani, Tri
AU - Siswandono,
AU - Meiyanto, Edy
AU - Sulistyowaty, Melanny Ika
AU - Purwanto, Bambang Tri
AU - Hardjono, Suko
N1 - Funding Information:
This research was supported by the Ministry of Research Technology and Higher Education, The Republic of Indonesia. The authors are grateful for access to conduct NMR and ESI-MS measurements at the Natural Science Center for Basic Research and Development (N-BARD) of the Graduate School of Biomedical and Health Sciences, Hiroshima University. The authors are grateful to Professor Yasumasha Bessho and Associate Professor Norihiro Ishida-Kitagawa for access to cell culture facility at the Laboratory of Gene Regulation, Department of Biological Science, Nara Institute of Science and Technology, Japan.
Publisher Copyright:
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria and 2018 The authors.
PY - 2018/8
Y1 - 2018/8
N2 - Purpose: To synthesise derivatives of N-allylthiourea and evaluate their anticancer activities against epidermal growth factor receptor (EGFR) using in silico and in vitro methods. Methods: Four compounds were synthesized using the Schotten-Baumann reaction. The structures of the synthesized compounds were confirmed using infrared (IR), proton nuclear magnetic resonance (1H-NMR), carbon nuclear magnetic resonence (13C-NMR) and electrospray ionization mass spectrometry (ESI-MS) methods. Molecular modeling was carried out with Molegro Virtual Docker version 5.5 through docking of the compounds onto the protein binding site of EGFR, with protein data bank (PBD) codes 1M17, 1XKK, and 3POZ. In vitro cytotoxicity was evaluated in MCF-7 cell lines using MTT assay. Results: The synthesized compounds showed lower Rerank Scores, relative to N-allylthiourea and hydroxyurea. The low Rerank Score values implied stable molecular bonds, and hence higher biological activities. In addition, the derivatives showed cytotoxicities against MCF-7 cell line (IC50: 0.21 – 0.38 mM) which were superior to those of N-allylthiourea (IC50: 5.22 mM) and hydroxyurea (IC50: 2.89 mM). Conclusion: The predicted anticancer activities of the synthesized compounds are consistent with results from in silico studies and assays of cytotoxicity against MCF-7 cell lines. Thus, N-allylthiourea derivatives can potentially be developed as anticancer drugs.
AB - Purpose: To synthesise derivatives of N-allylthiourea and evaluate their anticancer activities against epidermal growth factor receptor (EGFR) using in silico and in vitro methods. Methods: Four compounds were synthesized using the Schotten-Baumann reaction. The structures of the synthesized compounds were confirmed using infrared (IR), proton nuclear magnetic resonance (1H-NMR), carbon nuclear magnetic resonence (13C-NMR) and electrospray ionization mass spectrometry (ESI-MS) methods. Molecular modeling was carried out with Molegro Virtual Docker version 5.5 through docking of the compounds onto the protein binding site of EGFR, with protein data bank (PBD) codes 1M17, 1XKK, and 3POZ. In vitro cytotoxicity was evaluated in MCF-7 cell lines using MTT assay. Results: The synthesized compounds showed lower Rerank Scores, relative to N-allylthiourea and hydroxyurea. The low Rerank Score values implied stable molecular bonds, and hence higher biological activities. In addition, the derivatives showed cytotoxicities against MCF-7 cell line (IC50: 0.21 – 0.38 mM) which were superior to those of N-allylthiourea (IC50: 5.22 mM) and hydroxyurea (IC50: 2.89 mM). Conclusion: The predicted anticancer activities of the synthesized compounds are consistent with results from in silico studies and assays of cytotoxicity against MCF-7 cell lines. Thus, N-allylthiourea derivatives can potentially be developed as anticancer drugs.
KW - Cytotoxicity
KW - EGFR
KW - In silico
KW - MCF-7
KW - N-allylthiourea derivatives
KW - Synthesis
UR - http://www.scopus.com/inward/record.url?scp=85052883814&partnerID=8YFLogxK
U2 - 10.4314/tjpr.v17i8.20
DO - 10.4314/tjpr.v17i8.20
M3 - Article
AN - SCOPUS:85052883814
SN - 1596-5996
VL - 17
SP - 1607
EP - 1613
JO - Tropical Journal of Pharmaceutical Research
JF - Tropical Journal of Pharmaceutical Research
IS - 8
ER -